Evidence map›Paper›PMID 42666913›Full record

ArticleKidney international reports2026

Kidney Allograft Outcomes in Borderline and T Cell-Mediated Rejection With Microvascular Inflammation.

Wai H Lim, Jiayue Wang, Armando Teixeira-Pinto, Julie Ho, Ryan Gately, Dharshana Sabanayagam, Esther Ooi, Farzaneh Boroumand, K Shuvo Bakar, Lin Zhu and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Wai H LimNutrition and Health Innovation Research Institute, School of Medical and Health Sciences, Edith Cowan University, Perth, Australia.
Jiayue WangFaculty of Medicine and Health, Sydney School of Public Health, University of Sydney, Sydney, Australia.
Armando Teixeira-PintoFaculty of Medicine and Health, Sydney School of Public Health, University of Sydney, Sydney, Australia.
Julie HoDepartment of Internal Medicine, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Ryan GatelyDepartment of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, Australia.
Dharshana SabanayagamFaculty of Medicine and Health, Sydney School of Public Health, University of Sydney, Sydney, Australia.
Esther OoiNutrition and Health Innovation Research Institute, School of Medical and Health Sciences, Edith Cowan University, Perth, Australia.
Farzaneh BoroumandFaculty of Medicine and Health, Sydney School of Public Health, University of Sydney, Sydney, Australia.
K Shuvo BakarFaculty of Medicine and Health, Sydney School of Public Health, University of Sydney, Sydney, Australia.
Lin ZhuFaculty of Medicine and Health, Sydney School of Public Health, University of Sydney, Sydney, Australia.
Helen PilmoreDepartment of Renal Medicine, Auckland City Hospital, Auckland, New Zealand.
William MulleyDepartment of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia.
Jennifer LiDepartment of Renal Medicine and Transplantation, Westmead Hospital, Sydney, Australia.
Brian NankivellDepartment of Renal Medicine and Transplantation, Westmead Hospital, Sydney, Australia.
John KanellisDepartment of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia.
Peter NickersonDepartment of Internal Medicine, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Chris WiebeDepartment of Internal Medicine, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Germaine WongFaculty of Medicine and Health, Sydney School of Public Health, University of Sydney, Sydney, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Microvascular inflammation (MVI) is a hallmark feature of antibody-mediated rejection (ABMR), but its prognostic significance when it occurs with T-cell-mediated rejection (TCMR) in the absence of other ABMR features remains unclear. Methods: We examined the association between pure TCMR phenotypes, defined by the presence or absence of MVI, and graft survival using restricted mean survival time (RMST), and assessed interactions with rejection involving a "v" lesion. Results: Among 1614 recipients with first biopsy-proven pure TCMR (2010-2023), 85% had no MVI, 8% subthreshold MVI (Banff glomerulitis [g] + peritubular capillaritis [ptc] = 1), and 7% with MVI (g + ptc ≥ 2). Compared with TCMR without MVI, recipients with TCMR + MVI (hazard ratio [HR]; 95% confidence intervals [CI] 1.57 [1.06-2.34]) had a higher risk of all-cause graft loss, whereas subthreshold MVI was not associated with increased risk. The 5-year RMST was lowest in the MVI group (3.93 [3.53-4.26]), compared with the subthreshold group (4.39 [4.11- 4.60]) and the no MVI group (4.32 [4.24-4.40]). Rejection with a "v" lesion modified this association. Recipients with TCMR + MVI and positive "v" lesion had a 2.77-fold higher risk of graft loss (2.77 [1.64-4.67]), whereas no excess risk was observed in those without vascular lesions. Conclusion: Pure TCMR with MVI, particularly in the setting of a "v" lesion, represents a high-risk phenotype associated with poorer graft survival, warranting mechanistic investigations and targeted therapeutic strategies.

Indexed as

cellular rejectionkidney transplantmicrovascular inflammationregistryT cells rejection

Identifiers

PMID42666913
PMCPMC13524478

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.